Onychomycosis: Current trends in diagnosis and treatment

American Family Physician

Volumn 88, Issue 11, 2013, Pages 762-770

  Westerberg, Dyanne P ^a   Voyack, Michael J ^a  

^a Cooper Medical School of Rowan University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 UNDECENOIC ACID; 2 PROPANOL; AGERATINA PICHINCHENSIS EXTRACT; ALLYLAMINE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CICLOPIROX; CYANOACRYLATE; FLUCONAZOLE; HYDROQUINONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; NEODYMIUM; NON PRESCRIPTION DRUG; PHOTOSENSITIZING AGENT; PLANT EXTRACT; POTASSIUM HYDROXIDE; PROTON PUMP INHIBITOR; PYRROLE; TEA TREE OIL; TERBINAFINE; UNCLASSIFIED DRUG; WARFARIN; ZOLPIDEM TARTRATE;

ABDOMINAL PAIN; APPLICATION SITE DISCOLORATION; ARTICLE; BURNING SENSATION; CLINICAL TRIAL (TOPIC); DERMATITIS; DIARRHEA; ERYTHEMA; FINGERNAIL ONYCHOMYCOSIS; FLUORESCENCE MICROSCOPY; FOOT ULCER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; INGROWN NAIL; INJURY; LICHEN PLANUS; LIVER FUNCTION; LIVER TOXICITY; META ANALYSIS (TOPIC); MICROBIOLOGY; NAIL DISCOLORATION; NAIL PSORIASIS; NAUSEA AND VOMITING; NEODYMIUM YAG LASER; ONYCHOMYCOSIS; PERIUNGUAL ERYTHEMA; QT PROLONGATION; RASH; RISK FACTOR; SIDE EFFECT; SKIN BLOOD FLOW; SKIN DISCOLORATION; STEVENS JOHNSON SYNDROME; TOENAIL ONYCHOMYCOSIS; TREATMENT FAILURE; TREATMENT REFUSAL; TRICHOPHYTON; TWENTY NAIL DYSTROPHY;

EID: 84889003718     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Thomas J, Jacobson GA, Narkowicz CK, Peterson GM, Burnet H, Sharpe C. Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010;35(5):497-519.
2. Mayser P, Freund V, Budihardja D. Toenail onychomycosis in diabetic patients: issues and management. Am J Clin Dermatol. 2009;10(4): 211-220.
3. Surjushe A, Kamath R, Oberai C, et al. A clinical and mycological study of onychomycosis in HIV infection. Indian J Dermatol Venereol Leprol. 2007;73(6):397-401.
4. Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of ony-chomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol. 2000;14 (6): 466-469.
5. Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical clas-sifcation. J Am Acad Dermatol. 2011; 65 (6):1219-1227.
6. Faergemann J, Baran R. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol. 2003;149(suppl 65):1-4.
7. Allevato MA. Diseases mimicking onychomycosis. Clin Dermatol. 2010;28(2):164-177.
8. Alberhasky RC. Laboratory diagnosis of onychomycosis. Clin Podiatr Med Surg. 2004;21(4):565-578.
9. Shemer A, Davidovici B, Grunwald MH, Trau H, Amichai B. Comparative study of nail sampling techniques in onychomycosis. J Dermatol. 2009;36 (7):410-414.
10. Shemer A, Trau H, Davidovici B, Grunwald MH, Amichai B. Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail. J Dtsch Dermatol Ges. 2007; 5 (12): 1108-1111.
11. Snyder JW, Atlas RM, LaRocco MT. Reagents, stains, and media: mycology. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW, eds. Manual of Clinical Microbiology. 10th ed. Washington, DC: ASM Press; 2011:1767.
12. Kaur R, Kashyap B, Bhalla P. Onychomycosis-epidemiology, diagnosis and management. Indian J Med Microbiol. 2008;26(2):108-116.
13. Barak O, Asarch A, Horn T. PAS is optimal for diagnosing onychomyco-sis. J Cutan Pathol. 2010;37(10):1038-1040.
14. Wilsmann-Theis D, Sareika F, Bieber T, Schmid-Wendtner MH, Wenzel J. New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol. 2011;25(2):235-237.
15. Sato T, Takayanagi A, Nagao K, et al. Simple PCR-based DNA microar-ray system to identify human pathogenic fungi in skin. J Clin Microbiol. 2010;48(7):2357-2364.
16. Litz CE, Cavagnolo RZ. Polymerase chain reaction in the diagnosis of onychomycosis: a large, single-institute study. Br J Dermatol. 2010;163 (3): 511-514.
17. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic derma-tomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology. 2004;209(4):301-307.
18. Boyko EJ, Ahroni JH, Cohen V, Nelson KM, Heagerty PJ. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care. 2006;29(6):1202-1207.
19. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005;19(1):21-29.
20. Scher RK, Tavakkol A, Sigurgeirsson B, et al. Onychomycosis: diagnosis and defnition of cure. J Am Acad Dermatol. 2007;56(6):939-944.
21. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43(4 suppl):S70-S80.
22. Malay DS, Yi S, Borowsky P, Downey MS, Mlodzienski AJ. Effcacy of debridement alone versus debridement combined with topical antifun-gal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial. J Foot Ankle Surg. 2009;48(3):294-308.
23. Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150(3):537-544.
24. Lexi-Comp. http://online.lexi.com/crlsql/servlet/crlonline (subscription required). Accessed April 2, 2012.
25. Antifungal drugs. Treat Guidel Med Lett. 2009;7(88):95-102.
26. Bennett JE. Antifungal agents. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011:1571-1592.
27. Sweetman S, ed. Martindale. The Complete Drug Reference. London, U.K.: Pharmaceutical Press. Electronic version, Greenwood Village, Colo.: Thompson Reuters (Healthcare) Inc. Updated periodically.
28. Chang CH, Young-Xu Y, Kurth T, Orav JE, Chan AK. The safety of oral antifungal treatments for superfcial dermatophytosis and onychomyco-sis: a meta-analysis. Am J Med. 2007;120(9):791-798.
29. Gupta AK, Skinner AR. Onychomycosis in children: a brief overview with treatment strategies. Pediatr Dermatol. 2004;21(1):74-79.
30. Rotta I, Sanchez A, Gonçalves PR, Otuki MF, Correr CJ. Effcacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol. 2012;166(5):927-933.
31. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007;(3):CD001434.
32. Avner S, Nir N, Henri T. Combination of oral terbinafne and topical ciclopirox compared to oral terbinafne for the treatment of onychomy-cosis. J Dermatolog Treat. 2005;16(5-6):327-330.
33. Romero-Cerecero O, Zamilpa A, Jiménez-Ferrer JE, Rojas-Bribiesca G, Román-Ramos R, Tortoriello J. Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox [published correction appears in Planta Med. 2008;74(14):1767]. Planta Med. 2008;74 (12):1430-1435.
34. Rehder P, Nguyen TT. A new concept in the topical treatment of onycho-mycosis with cyanoacrylate, undecylenic acid, and hydroquinone. Foot Ankle Spec. 2008;1(2):93-96.
35. Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870-and 930-nm light exposure. J Am Podiatr Med Assoc. 2010;100(3):166-177.
36. Buck DS, Nidorf DM, Addino JG. Comparison of two topical preparations for the treatment of onychomycosis: Melaleuca alternifolia (tea tree) oil and clotrimazole. J Fam Pract. 1994;38(6):601-605.
37. Derby R, Rohal P, Jackson C, Beutler A, Olsen C. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med. 2011; 24 (1): 69-74.
38. Kimura U, Takeuchi K, Kinoshita A, Takamori K, Hiruma M, Suga Y. Treating onychomycoses of the toenail: clinical effcacy of the sub-millisecond 1,064 nm Nd:YAG laser using a 5 mm spot diameter. J Drugs Dermatol. 2012;11(4):496-504.
39. Jennings MB, Pollak R, Harkless LB, Kianifard F, Tavakkol A. Treatment of toenail onychomycosis with oral terbinafne plus aggressive debride-ment: IRON-CLAD, a large, randomized, open-label, multicenter trial. J Am Podiatr Med Assoc. 2006;96(6):465-473.
40. Gupta AK, Simpson F. Newly approved laser systems for onychomycosis. J Am Podiatr Med Assoc. 2012;102(5):428-430.
41. 510(k) summary: Noveon (Model LS1100-01-0968) dual wavelength leser instrument. http://www.accessdata.fda.gov/cdrh_docs/pdf7/K071815.pdf. Accessed January 20, 2012.
42. Landsman AS, Robbins AH. Treatment of mild, moderate, and severe onychomycosis using 870-and 930-nm light exposure: some follow-up observations at 270 days. J Am Podiatr Med Assoc. 2012; 102 (2):169-171.
43. Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, Apalla Z, Ioannides D. Photodynamic therapy for distal and lateral subungual toenail ony-chomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90(2):216-217.
44. Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003;149(suppl 65):5-9.
45. Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomy-cosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol. 2010; 62 (3):411-414.